Abstract mRNA vaccines have emerged as a revolutionary tool to generate rapid and
precise immune responses against infectious diseases and cancers. Compared with …

Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an
ongoing research area that started before these versatile nanoparticles were successfully …

In late 2020, the US Food and Drug Administration (FDA) approved a lipid-based mRNA
vaccine for the prevention of COVID-19, which has pushed this field to be more closely …

Lipid nanoparticles (LNPs) are currently the most promising clinical nucleic acids drug
delivery vehicles. LNPs prevent the degradation of cargo nucleic acids during blood …

Cancer immunotherapy, which harnesses the power of the immune system, has shown
immense promise in the fight against malignancies. Messenger RNA (mRNA) stands as a …

mRNA vaccines have evolved as promising cancer therapies. These vaccines can encode
tumor-allied antigens, thus enabling personalized treatment approaches. They can also …

Throughout the last decades, mRNA vaccines have been developed as a cancer
immunotherapeutic and the technology recently gained momentum during the COVID-19 …

Abstract mRNA therapeutics have emerged as powerful tools for cancer immunotherapy in
accordance with their superiority in expressing all sequence‐known proteins in vivo. In …

Lipid‐based nanoparticles have recently shown great promise, establishing themselves as
the gold standard in delivering novel RNA therapeutics. However, research on the effects of …

Messenger RNA (mRNA) recently emerged as an appealing alternative to treat and prevent
diseases ranging from cancer and Alzheimer's disease to COVID-19 with significant clinical …